Home > Resources > Whitepapers > Is Your Biologic At Risk For Delays, Disruptions Or Audits?

Is Your Biologic At Risk For Delays, Disruptions Or Audits?

December 13, 2018

Thus, it’s no surprise that the world’s largest pharmaceutical companies have invested a combined $1.5 billion over the past five years to focus primarily on the advance of new biologics and biosimilars. While the North American economy represents a full 40 percent of this rapidly expanding market, the growth of overseas manufacturing facilities has created a network of opportunities for agile contract manufacturers around the world.

Spotlight

Viroclinics Biosciences BV

Viroclinics Biosciences operates at a global level, being the preferred virology testing laboratory for several of the top-10 Biopharmaceutical companies. As a virology contract research organization, we serve the biopharmaceutical community with our preclinical, clinical diagnostic, research & development and clinical trial logistics services. Our extensive experience with clinical and preclinical studies for viruses, including our specialty in respiratory viruses, puts us at the forefront for supporting the development of vaccines, antibodies and antiviral compounds targeting viral infectious diseases.

OTHER WHITEPAPERS

Growing a circular economy with fungalbiotechnology

whitePaper | October 22, 2022

Fungi have the ability to transform organic materials into a rich and diverse set of useful products and provide distinct opportunities for tackling the urgent challenges before all humans

Read More

Mainstreaming Cell & Gene Therapies

whitePaper | October 27, 2022

The cell and gene therapy (CGT) market is rapidly transitioning from ultra-niche cutting-edge science to approved and available therapies that can address previously intractable and often devastating diseases.

Read More

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO).

Read More

Microfluidics: Big developments on thesmall scale

whitePaper | February 23, 2023

Life sciences is a blanket term used to describe the study of all things relative to living organisms, such as biology, physiology, and biochemistry.

Read More

A REVIEW OF THE RESEARCH TRENDS AND DEVELOPMENTS

whitePaper | May 9, 2022

In the last decade, there has been an encouraging shift in research, clinical development, and commercial activity to exploit the many biological roles of ribonucleic acid (RNA) for use in medicine.

Read More

Scalable Rubella production in scale-X™ bioreactor with MRC-5 cells

whitePaper | November 18, 2022

Due to vaccine delivery gap for Rubella disease, global immunization is still limited in some parts of the world. In this paper we will demonstrate how one scale-X™ carbo fixed-bed bioreactor system.

Read More

Growing a circular economy with fungalbiotechnology

whitePaper | October 22, 2022

Fungi have the ability to transform organic materials into a rich and diverse set of useful products and provide distinct opportunities for tackling the urgent challenges before all humans

Read More

Mainstreaming Cell & Gene Therapies

whitePaper | October 27, 2022

The cell and gene therapy (CGT) market is rapidly transitioning from ultra-niche cutting-edge science to approved and available therapies that can address previously intractable and often devastating diseases.

Read More

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO).

Read More

Microfluidics: Big developments on thesmall scale

whitePaper | February 23, 2023

Life sciences is a blanket term used to describe the study of all things relative to living organisms, such as biology, physiology, and biochemistry.

Read More

A REVIEW OF THE RESEARCH TRENDS AND DEVELOPMENTS

whitePaper | May 9, 2022

In the last decade, there has been an encouraging
shift in research, clinical development, and commercial activity to exploit the many biological roles of ribonucleic acid (RNA) for use in medicine.

Read More

Scalable Rubella production in scale-X™ bioreactor with MRC-5 cells

whitePaper | November 18, 2022

Due to vaccine delivery gap for Rubella disease, global immunization is still limited in some parts of the world. In this paper we will demonstrate how one scale-X™ carbo fixed-bed bioreactor system.

Read More

More Whitepapers

Spotlight

Viroclinics Biosciences BV

Viroclinics Biosciences operates at a global level, being the preferred virology testing laboratory for several of the top-10 Biopharmaceutical companies. As a virology contract research organization, we serve the biopharmaceutical community with our preclinical, clinical diagnostic, research & development and clinical trial logistics services. Our extensive experience with clinical and preclinical studies for viruses, including our specialty in respiratory viruses, puts us at the forefront for supporting the development of vaccines, antibodies and antiviral compounds targeting viral infectious diseases.

Events

8th International Conference on Bio-Sensing Technology

Conference

8th International Conference on Bio-Sensing Technology

Conference